메뉴 건너뛰기
Drugs and Therapy Perspectives
Volumn 14, Issue 1, 1999, Pages 1-5
Will cilostazol improve care for patients with intermittent claudication?
[No Author Info available]
Author keywords

[No Author keywords available]
Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 ISOENZYME; NAFTIDROFURYL; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR;
EID: 0033526905     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-199914010-00001     Document Type: Review
Times cited : (1)
References (15)
  • 1
    • 0033014722 scopus 로고    scopus 로고
    • Cilostazol: A viewpoint
    • Dawson D. Cilostazol: a viewpoint. Drugs Aging 1999 Jan; 14 (1): 72-3
    • (1999) Drugs Aging , vol.14 , Issue.1 , pp. 72-73
    • Dawson, D.1
  • 2
    • 0026827946 scopus 로고
    • Pharmacological approaches to the treatment of intermittent claudication
    • Mar-Apr
    • Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992 Mar-Apr; 2 (2): 125-36
    • (1992) Drugs Aging , vol.2 , Issue.2 , pp. 125-136
    • Bevan, E.G.1    Waller, P.C.2    Ramsay, L.E.3
  • 3
    • 0030830516 scopus 로고    scopus 로고
    • Current and future drug therapies for claudication
    • Hiatt WR. Current and future drug therapies for claudication. Vasc Med 1997; 2 (3): 257-62
    • (1997) Vasc Med , vol.2 , Issue.3 , pp. 257-262
    • Hiatt, W.R.1
  • 4
    • 0029997708 scopus 로고    scopus 로고
    • Pentoxifylline and naftidrofuryl: Commonly used drugs for intermittent claudication
    • May 27
    • Pentoxifylline and naftidrofuryl: commonly used drugs for intermittent claudication. Drug Ther Perspect 1996 May 27; 7 (10): 1-5
    • (1996) Drug Ther Perspect , vol.7 , Issue.10 , pp. 1-5
  • 5
    • 0029121883 scopus 로고
    • Clinical trials for claudication assessment of exercise performance, functional status and clinical end points
    • Hiatt WR, Hirsch A, Regensteiner JG, et al. Clinical trials for claudication assessment of exercise performance, functional status and clinical end points. Circulation 1995; 92: 614-21
    • (1995) Circulation , vol.92 , pp. 614-621
    • Hiatt, W.R.1    Hirsch, A.2    Regensteiner, J.G.3
  • 6
    • 0026601499 scopus 로고
    • Medical treatment of peripheral vascular disease, good or bad?
    • Duprez D, Clements DL. Medical treatment of peripheral vascular disease, good or bad? Eur Heart J 1992; 13: 149-51
    • (1992) Eur Heart J , vol.13 , pp. 149-151
    • Duprez, D.1    Clements, D.L.2
  • 7
    • 0033089207 scopus 로고    scopus 로고
    • Cilostazol approved for use in intermittent claudication
    • Mar
    • Cilostazol approved for use in intermittent claudication. Am J Health-Syst Pharm 1999 Mar; 56: 404
    • (1999) Am J Health-Syst Pharm , vol.56 , pp. 404
  • 9
    • 0004223602 scopus 로고    scopus 로고
    • London: The Pharmaceutical Press, Mar
    • British National Formulary. No. 37. London: The Pharmaceutical Press, 1999 Mar: 103-4
    • (1999) British National Formulary. No. 37 , pp. 103-104
  • 11
    • 0002837634 scopus 로고    scopus 로고
    • Cilostazol or pentoxifylline for claudication?
    • Dawson DL, Beebe HG, Davidson MH, et al. Cilostazol or pentoxifylline for claudication? [abstract]. Circulation 1998; 98 (17) Suppl. I: I-12
    • (1998) Circulation , vol.98 , Issue.17 SUPPL. I
    • Dawson, D.L.1    Beebe, H.G.2    Davidson, M.H.3
  • 12
    • 0027433339 scopus 로고
    • Phosphodiesterase III inhibitors: Long-term risks and short-term benefits
    • Aug
    • Cruickshank JM. Phosphodiesterase III inhibitors: long-term risks and short-term benefits. Cardiovasc Drugs Ther 1993 Aug; 7 (4): 655-60
    • (1993) Cardiovasc Drugs Ther , vol.7 , Issue.4 , pp. 655-660
    • Cruickshank, J.M.1
  • 13
    • 4243444696 scopus 로고    scopus 로고
    • The effects of CYP3A4 inhibition by erythromycin on the metabolism of cilostazol
    • Suri A, Forbes WP, Bramer SL. The effects of CYP3A4 inhibition by erythromycin on the metabolism of cilostazol [abstract]. Pharm Res 1997; 14 (11) Suppl.: S-562
    • (1997) Pharm Res , vol.14 , Issue.11 SUPPL.
    • Suri, A.1    Forbes, W.P.2    Bramer, S.L.3
  • 14
    • 0032954069 scopus 로고    scopus 로고
    • Estimation of walking distance in intermittent claudication: Need for standardization
    • Duprez D, de Backer T, de Buyzere M, et al. Estimation of walking distance in intermittent claudication: need for standardization. Eur Heart J 1999; 20: 641-4
    • (1999) Eur Heart J , vol.20 , pp. 641-644
    • Duprez, D.1    De Backer, T.2    De Buyzere, M.3
  • 15
    • 0024266378 scopus 로고
    • Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published trials, 1965-1985
    • Nov
    • Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published trials, 1965-1985. Br J Clin Pharmacol 1988 Nov; 26: 569-76
    • (1988) Br J Clin Pharmacol , vol.26 , pp. 569-576
    • Cameron, H.A.1    Waller, P.C.2    Ramsay, L.E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.